secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2026-03-18T23:59:59+00:00
Accession:  0001193125-26-113949
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

4DMT FY2025 net loss $140M; cash $514M; 4D-150 Phase 3 enrollment completed
---------------------------------------------------------------------------

- Net loss of $140M in FY2025 versus $161M in FY2024; R&D expenses $196M (up from $141M).
- Cash, equivalents and securities $514M; expected to fund operations into H2 2028.
- 4D-150 4FRONT-1 Phase 3 wet AMD enrollment completed; topline data expected H1 2027.
- Otsuka partnership for 4D-150 in Asia-Pacific provided $85M upfront; up to $336M milestones plus royalties.
- Leadership additions: new CFO Kristian Humer, CMO Julie Clark, CTO Katy Barglow, Board member Glenn Sblendorio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000119312526113949/0001193125-26-113949-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000119312526113949/fdmt-20260318.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-113949

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer